AbbVie (NYSE: ABBV) director granted 71 stock equivalent units in fee plan

Rhea-AI Filing Summary

Quaggin Susan E reported acquisition or exercise transactions in this Form 4 filing.

AbbVie Inc. director Susan E. Quaggin reported a compensation-related award of 71 stock equivalent units tied to AbbVie common stock at a reference value of $217.49 per unit. Following this grant, her balance in these units increased to 784 stock equivalent units.

The units represent director fees credited to a stock equivalent unit account under a grantor trust established by the director and are generally paid in cash at around age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock, and the balance also reflects units accumulated through a dividend reinvestment feature.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Quaggin Susan E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Equivalent Units	71	$217.49	$15K

Holdings After Transaction: Stock Equivalent Units — 784 shares (Direct)

Footnotes (1)

1. Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Key Figures

Stock equivalent units granted: 71 units Reference value per unit: $217.49 per unit Total units after transaction: 784 units

3 metrics

Stock equivalent units granted 71 units Grant of stock equivalent units on 2026-03-31

Reference value per unit $217.49 per unit Conversion or exercise price for stock equivalent units

Total units after transaction 784 units Stock equivalent unit balance following the grant

Key Terms

Stock Equivalent Units, grantor trust, dividend reinvestment feature

3 terms

Stock Equivalent Units financial

"Director fees credited to a stock equivalent unit account under a grantor trust"

Stock equivalent units are financial claims or instruments that are treated as if they were actual shares for purposes like calculating ownership, dilution, and earnings per share. Think of them as promises or placeholders for future slices of company pie—options, restricted units, or convertible securities—that don’t yet sit on the table but will reduce each existing slice when converted. Investors track them because they change how much of a company each share really represents and can affect valuation and voting power.

grantor trust financial

"under a grantor trust established by the director and paid, in cash, generally at age 65"

A grantor trust is a legal arrangement where the person who puts assets into the trust keeps enough control or rights that, for tax and legal purposes, those assets are treated as still belonging to that person. For investors, that matters because income, gains and losses generated by the trust typically flow through to the grantor (or directly to investors) for tax reporting and distributions, affecting after-tax returns and cash flow predictability — think of it like a mailbox that forwards all the mail back to the sender rather than holding it inside.

dividend reinvestment feature financial

"Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quaggin Susan E

(Last) (First) (Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO ILLINOIS 60064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Equivalent Units	$217.49	03/31/2026		A		71		(1)	(1)	Common Stock	71	$217.49	784(2)	D

Explanation of Responses:

1. Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

	/s/ T.O. Odutayo, Attorney-in-Fact for Susan E. Quaggin	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did AbbVie (ABBV) director Susan E. Quaggin report in this Form 4?

Susan E. Quaggin reported receiving 71 stock equivalent units as a compensation-related grant. These units are tied to AbbVie’s stock value and are credited as director fees in a stock equivalent unit account, increasing her total balance to 784 units after the transaction.

How many AbbVie stock equivalent units does Susan E. Quaggin hold after this transaction?

After this transaction, Susan E. Quaggin holds 784 stock equivalent units. This total includes the newly granted 71 units and prior units accumulated over time, including those acquired through a dividend reinvestment feature linked to AbbVie’s stock performance and paid later in cash.

What are AbbVie stock equivalent units reported in this Form 4 for ABBV?

The stock equivalent units are director fees credited to a stock equivalent unit account under a grantor trust. They earn the same return as if invested directly in AbbVie stock and are generally paid out in cash around age 65 or upon retirement from the board.

How is Susan E. Quaggin’s AbbVie director compensation structured in this filing?

Part of Susan E. Quaggin’s director compensation is credited as stock equivalent units rather than immediate cash. These units mirror AbbVie stock performance, accumulate over time, include a dividend reinvestment feature, and are generally paid out in cash at retirement or approximately age 65.

Does this AbbVie Form 4 show an open-market buy or sell of ABBV shares?

No, the Form 4 shows a grant of 71 stock equivalent units as compensation, not an open-market purchase or sale. The units are bookkeeping entries in a grantor trust that track AbbVie stock returns and will be settled in cash later, rather than current share trading.